Omega Fund Management, LLC reported 10 positions worth $185.69M for the quarter ended Jun 30, 2026, up 13.8% on the prior quarter. It opened 1 new position, added to 0, trimmed 1 and exited 1. Its largest holding is Bicara Therapeutics Inc. at 29.1% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ODTX Odyssey Therapeutics, Inc. | +2,893 | – | $54.13K | 0.029% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| ODTX Odyssey Therapeutics, Inc. | +2,893 | $54.13K | 0.029% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| REPL Replimune Group, Inc. | -248.7K | $1.91M | 1.17% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | BCAX Bicara Therapeutics Inc. | Healthcare | 1.82M | $54.10M | 29.14% | -570.0K | -23.8% | Reduced | 2.68% |
| 2 | NUVB Nuvation Bio Inc. | Healthcare | 8.08M | $45.90M | 24.72% | 0 | 0.0% | Unchanged | 2.31% |
| 3 | KMTS Kestra Medical Technologies, Ltd. | Healthcare | 1.02M | $26.00M | 14% | 0 | 0.0% | Unchanged | 1.75% |
| 4 | BBOT BridgeBio Oncology Therapeutics, Inc. | Healthcare | 3.29M | $25.07M | 13.5% | 0 | 0.0% | Unchanged | 4.11% |
| 5 | BBNX Beta Bionics, Inc. | Healthcare | 1.32M | $20.62M | 11.11% | 0 | 0.0% | Unchanged | 2.95% |
| 6 | ALMS Alumis Inc. | Healthcare | 241.3K | $6.79M | 3.66% | 0 | 0.0% | Unchanged | 0.19% |
| 7 | SANA Sana Biotechnology, Inc. | Healthcare | 843.8K | $2.94M | 1.59% | 0 | 0.0% | Unchanged | 0.28% |
| 8 | IMA ImageneBio, Inc. | Healthcare | 455.4K | $2.69M | 1.45% | 0 | 0.0% | Unchanged | 2.82% |
| 9 | ENGN enGene Therapeutics Inc. | Healthcare | 876.4K | $1.52M | 0.816% | 0 | 0.0% | Unchanged | 1.26% |
| 10 | ODTX Odyssey Therapeutics, Inc. | Healthcare | 2,893 | $54.13K | 0.029% | +2,893 | – | New | 0.01% |
Tip. Select a row to see that position’s full history at Omega Fund Management.
As of its Q2 2026 13F filing, Omega Fund Management, LLC’s five largest positions were Bicara Therapeutics Inc. (BCAX) at 29.1%, Nuvation Bio Inc. (NUVB) at 24.7%, Kestra Medical Technologies, Ltd. (KMTS) at 14.0%, BridgeBio Oncology Therapeutics, Inc. (BBOT) at 13.5%, Beta Bionics, Inc. (BBNX) at 11.1% of the reported portfolio.
Omega Fund Management, LLC reported a 13F portfolio worth $185.69M across 10 positions for Q2 2026. That is up 13.8% from the previous quarter.
Its largest purchases by value were Odyssey Therapeutics, Inc. ($54.13K). It opened 1 new positions.
Its largest sales by value were Bicara Therapeutics Inc. ($16.92M), Replimune Group, Inc. ($1.91M). It exited 1 positions entirely.
From the Form 13F-HR reports Omega Fund Management, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.